Acquired resistance to immunotherapy by physical barriers with cancer cell–expressing collagens in non–small cell lung cancer

M Manli Wang Y Yiyun Wang (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) X Xiangyu Pan (Key Laboratory of Green Printing, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China) B Bo Wang Y Yuying Wang (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) X Xiangmeng Luo (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) X Xiaofeng Deng (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) L Li Liu X Xuelan Chen (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) X Xiaoqian Zhai (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) B Baohong Wu (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Q Qi Zhang Y Yifeng Ren (Hospital of Chengdu University of Traditional Chinese Medicine) J Jia Li X Xiaoyu Li F Fujun Cao (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Y Yang Yang X Xintong Deng (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) R Runhong Li (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Z Zhenghao Lu (Chengdu OrganoidMed Medical Laboratory, West China Health Valley) P Ping Tan (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) J Jingyao Chen (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Y Yan Li Y Yanyang Liu (Lung Cancer Treatment Center, West China Hospital, Sichuan University) J Jiewei Liu (Lung Cancer Treatment Center, West China Hospital, Sichuan University) Y Yuan Wang H Hongxin Deng (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Z Zhaoming Su (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) W Weiya Wang (Department of Pathology, West China Hospital, Sichuan University) Y Yongsheng Wang (Division of Thoracic Tumor Multimodality Treatment Cancer Center, West China Hospital, Sichuan University) S Shengyong Yang C Chengjian Zhao (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) J Jianxin Xue (Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Y Yuquan Wei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) K Kang Zhang (Qi Biodesign, Beijing, China.) F Feifei Na (Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Y Yu Liu C Chong Chen (Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University)

Abstract

Immunotherapy has become the standard treatment for many types of cancers, but an increasing number of patients who initially respond to these treatments develop acquired immunotherapy resistance (AIR). Here, we recapitulated the entire process of immunotherapy from response to AIR in mice with non–small cell lung cancer (NSCLC). With implanted tumor organoids derived from these models and serial transplants, we demonstrated that tumor cell–intrinsic mechanisms contributed significantly to AIR. Single-cell RNA sequencing and electron microscope assays revealed that resistant tumor cell–expressing collagens, including Col3a1 and Col6a1 , formed multiple physical barriers surrounding tumor cells. Disruption of these barriers by collagenase or knockout of both Col3a1 and Col6a1 in tumor cells could sensitize the tumors of AIR. Mechanistically, the TGFβ pathway was upregulated upon immunotherapy, and treatment with TGFβ significantly increased the expression levels of both Col3a1 and Col6a1 in tumor cells. COL3A1 formed a castle-like barrier for a cluster of tumor cells and prevented T cell infiltration, while COL6A1 formed an armor-like barrier surrounding individual tumor cells to protect them against direct T cell attack. Our data reveal a tumor cell–intrinsic mechanism of AIR, mediated by collagen-containing physical barriers, which immediately suggests a clinical treatment option.

Article Details

Volume / Issue Vol. 122, Issue 24
Published June 17, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (38)

M

Manli Wang

Y

Yiyun Wang

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

X

Xiangyu Pan

Key Laboratory of Green Printing, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China

B

Bo Wang

Y

Yuying Wang

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

X

Xiangmeng Luo

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

X

Xiaofeng Deng

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

L

Li Liu

X

Xuelan Chen

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

X

Xiaoqian Zhai

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

B

Baohong Wu

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Q

Qi Zhang

Y

Yifeng Ren

Hospital of Chengdu University of Traditional Chinese Medicine

J

Jia Li

X

Xiaoyu Li

F

Fujun Cao

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Y

Yang Yang

X

Xintong Deng

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

R

Runhong Li

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Z

Zhenghao Lu

Chengdu OrganoidMed Medical Laboratory, West China Health Valley

P

Ping Tan

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

J

Jingyao Chen

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Y

Yan Li

Y

Yanyang Liu

Lung Cancer Treatment Center, West China Hospital, Sichuan University

J

Jiewei Liu

Lung Cancer Treatment Center, West China Hospital, Sichuan University

Y

Yuan Wang

H

Hongxin Deng

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Z

Zhaoming Su

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

W

Weiya Wang

Department of Pathology, West China Hospital, Sichuan University

Y

Yongsheng Wang

Division of Thoracic Tumor Multimodality Treatment Cancer Center, West China Hospital, Sichuan University

S

Shengyong Yang

C

Chengjian Zhao

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

J

Jianxin Xue

Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Y

Yuquan Wei

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

K

Kang Zhang

Qi Biodesign, Beijing, China.

F

Feifei Na

Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University

Y

Yu Liu

C

Chong Chen

Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University